“Martin Shkreli Faces Contempt Push by FTC and Seven States Over Alleged Biopharma Stock In” — what this page in the network covers. Martin Shkreli, the former pharmaceutical executive often called 'Pharma Bro,' is again in the crosshairs of regulators. The Federal Trade Commission, joined by seven states, has asked a federal court to hold Shkreli in contempt, alleging he violated a prior order barring him from influencing biopharma stock prices. The move marks the latest chapter in a long-running legal saga for Shkreli, who gained notoriety for hiking the price of a life-saving drug by more than 4,000% while CEO of Turing Pharmaceuticals.
He was later convicted of securities fraud and sentenced to seven years in prison, but the FTC says his post-release conduct still poses a risk to markets and investors. The contempt action underscores regulators' determination to enforce lifetime bans and curb potential market manipulation in the volatile biotech sector. The full version stays on the original page, which this listing opens directly.